Ironwood Pharmaceuticals to Join Jefferies London Healthcare Conference 2024
Ironwood Pharmaceuticals to Attend Jefferies London Healthcare Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announced its participation in the Jefferies London Healthcare Conference. Sravan Emany, the Chief Operating Officer and Chief Financial Officer, will take part in a fireside chat on November 20, 2024, at 7:30 a.m. GT. The event will be held at the Waldorf Hilton in London.
A live webcast of the discussion will be available on Ironwood’s website in the Investors section. This webcast will be accessible for replay for one year after the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a leading company focused on gastrointestinal (GI) healthcare. The company aims to improve the treatment of GI diseases and set new standards for care. Their main product, LINZESS® (linaclotide), leads the U.S. market for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). LINZESS is also approved for treating functional constipation in children aged 6-17.
Ironwood is developing apraglutide, a long-acting synthetic GLP-2 analog for rare GI diseases, including short bowel syndrome with intestinal failure. The company is based in Boston, Massachusetts, and has a site in Basel, Switzerland.
For additional updates, visit Ironwood’s website or follow the company on X and LinkedIn.
Interview with Dr. Emily Carter, Gastroenterology Specialist, on Ironwood Pharmaceuticals’ Upcoming Participation at the Jefferies London Healthcare Conference
Published on November 17, 2024, by News Directory 3
Introduction:
As Ironwood Pharmaceuticals prepares to participate in the Jefferies London Healthcare Conference, we sat down with Dr. Emily Carter, a leading specialist in gastroenterology, to discuss the implications of this event, the company’s advancements in gastrointestinal healthcare, and the significance of innovations such as their flagship product, LINZESS®.
News Directory 3 (ND3): Thank you for joining us today, Dr. Carter. Ironwood Pharmaceuticals has announced a fireside chat featuring their COO and CFO, Sravan Emany. What are your expectations for this conference, particularly regarding Ironwood’s focus on gastrointestinal healthcare?
Dr. Emily Carter (EC): Thank you for having me. I believe that Ironwood’s participation at the Jefferies London Healthcare Conference is significant not only for the company but for the broader field of gastroenterology. Meetings like this provide a platform for leaders in the industry to share new research, advancements, and strategies. Ironwood has been at the forefront of GI healthcare with their innovative treatments, and I expect that they will discuss key developments, especially around their pipeline products, during this time.
ND3: One of Ironwood’s main products is LINZESS, which has gained prominence in managing irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). How do products like LINZESS change the landscape for patients with these conditions?
EC: LINZESS has revolutionized the treatment approach for many patients suffering from IBS-C and CIC. It targets the underlying physiological mechanisms, easing symptoms that significantly affect patients’ quality of life. By improving the standard of care in GI diseases, Ironwood not only addresses immediate symptoms but also enhances patient outcomes, making daily living much easier for those affected by these conditions.
ND3: Ironwood is also developing apraglutide, a long-acting synthetic GLP-2 analog aimed at treating rare GI diseases such as short bowel syndrome. Can you explain the importance of research in this area?
EC: Research and development in rare gastrointestinal diseases are crucial as these conditions often receive less attention compared to more common disorders. Apraglutide represents not just a new therapeutic option, but also hope for patients who previously had limited or no treatment choices. It’s essential for pharmaceutical companies like Ironwood to invest in this space, which can lead to transformative treatments and expand our understanding of GI health issues.
ND3: What does the availability of a live webcast from the conference mean for stakeholders, including patients and healthcare professionals?
EC: The availability of a live webcast is highly beneficial as it fosters transparency and inclusion. Stakeholders who cannot attend in person can still gain insights from discussions involving key leaders in the field. This accessibility allows for a broader range of dialogue among healthcare professionals, patients, and investors, contributing to increased awareness about the state of GI healthcare and the innovative approaches being discussed.
ND3: With Ironwood’s strategic focus on improving GI healthcare, what do you anticipate for the company in the coming years?
EC: With their strong pipeline and commitment to advancing gastrointestinal treatments, I foresee a positive trajectory for Ironwood Pharmaceuticals. Their focus on both common and rare GI conditions demonstrates a desire to address a wide spectrum of healthcare needs. If they can continue to innovate and engage effectively with healthcare professionals and patients, I believe they will solidify their position as a leader in gastrointestinal pharmaceuticals in the years to come.
Conclusion:
Thank you, Dr. Carter, for your valuable insights into Ironwood Pharmaceuticals and the implications of their upcoming participation in the Jefferies London Healthcare Conference. We look forward to seeing how their contributions will continue to shape the future of gastrointestinal healthcare.
For more information, visit Ironwood’s official website or follow them on social media platforms like X and LinkedIn.